214 related articles for article (PubMed ID: 37247499)
1. Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile.
Wang T; Guo K; Zhang D; Wang H; Yin J; Cui H; Wu W
Int Immunopharmacol; 2023 Jul; 120():110368. PubMed ID: 37247499
[TBL] [Abstract][Full Text] [Related]
2. Constructed Risk Prognosis Model Associated with Disulfidptosis lncRNAs in HCC.
Jia X; Wang Y; Yang Y; Fu Y; Liu Y
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139458
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.
Xiong Y; Kong X; Mei H; Wang J; Zhou S
Sci Rep; 2023 Dec; 13(1):22218. PubMed ID: 38097783
[TBL] [Abstract][Full Text] [Related]
4. Construction of a novel disulfidptosis-related signature for improving outcomes in hepatocellular carcinoma: Observational study.
Chen X; Liang Q; Zhou Y
Medicine (Baltimore); 2023 Oct; 102(40):e35423. PubMed ID: 37800779
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of a novel molecular classification based on disulfidptosis-related genes to predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.
Yang L; Zhang W; Yan Y
Aging (Albany NY); 2023 Jul; 15(13):6135-6151. PubMed ID: 37399661
[TBL] [Abstract][Full Text] [Related]
6. Novel application of the ferroptosis-related genes risk model associated with disulfidptosis in hepatocellular carcinoma prognosis and immune infiltration.
Wei J; Wang J; Chen X; Zhang L; Peng M
PeerJ; 2024; 12():e16819. PubMed ID: 38317842
[TBL] [Abstract][Full Text] [Related]
7. Disulfidptosis-related signatures for prognostic and immunotherapy reactivity evaluation in hepatocellular carcinoma.
Zhao J; Luo Z; Fu R; Zhou J; Chen S; Wang J; Chen D; Xie X
Eur J Med Res; 2023 Dec; 28(1):571. PubMed ID: 38057871
[TBL] [Abstract][Full Text] [Related]
8. Disulfidptosis-related signature predicts prognosis and characterizes the immune microenvironment in hepatocellular carcinoma.
Tang J; Peng X; Xiao D; Liu S; Tao Y; Shu L
Cancer Cell Int; 2024 Jan; 24(1):19. PubMed ID: 38195525
[TBL] [Abstract][Full Text] [Related]
9. Identification of disulfidptosis related subtypes, characterization of tumor microenvironment infiltration, and development of DRG prognostic prediction model in RCC, in which
Xu K; Zhang Y; Yan Z; Wang Y; Li Y; Qiu Q; Du Y; Chen Z; Liu X
Front Immunol; 2023; 14():1205250. PubMed ID: 37426643
[TBL] [Abstract][Full Text] [Related]
10. Integrative analysis of disulfidptosis and immune microenvironment in hepatocellular carcinoma: a putative model and immunotherapeutic strategies.
Yang T; Liu J; Liu F; Lei J; Chen S; Ma Z; Ke P; Yang Q; Wen J; He Y; Duan J; Zeng X
Front Immunol; 2023; 14():1294677. PubMed ID: 38235128
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
Zhao S; Wang L; Ding W; Ye B; Cheng C; Shao J; Liu J; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1180404. PubMed ID: 37152941
[TBL] [Abstract][Full Text] [Related]
12. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
[TBL] [Abstract][Full Text] [Related]
13. A novel disulfidptosis-related lncRNA signature for predicting prognosis and potential targeted therapy in hepatocellular carcinoma.
Zhang H; Wang J; Yang M
Medicine (Baltimore); 2024 Jan; 103(4):e36513. PubMed ID: 38277541
[TBL] [Abstract][Full Text] [Related]
14. Molecular subtypes of disulfidptosis-regulated genes and prognosis models for predicting prognosis, tumor microenvironment infiltration, and therapeutic response in hepatocellular carcinoma.
Qu J; Guan H; Zheng Q; Sun F
Int J Biol Macromol; 2024 Mar; 261(Pt 1):129584. PubMed ID: 38246443
[TBL] [Abstract][Full Text] [Related]
15. Pancancer analysis reveals the role of disulfidptosis in predicting prognosis, immune infiltration and immunotherapy response in tumors.
Huang J; Xu Z; Chen D; Zhou C; Shen Y
Medicine (Baltimore); 2023 Dec; 102(52):e36830. PubMed ID: 38206694
[TBL] [Abstract][Full Text] [Related]
16. Identification a unique disulfidptosis classification regarding prognosis and immune landscapes in thyroid carcinoma and providing therapeutic strategies.
Feng Z; Zhao Q; Ding Y; Xu Y; Sun X; Chen Q; Zhang Y; Miao J; Zhu J
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11157-11170. PubMed ID: 37347261
[TBL] [Abstract][Full Text] [Related]
17. Machine learning-based disulfidptosis-related lncRNA signature predicts prognosis, immune infiltration and drug sensitivity in hepatocellular carcinoma.
Pu L; Sun Y; Pu C; Zhang X; Wang D; Liu X; Guo P; Wang B; Xue L; Sun P
Sci Rep; 2024 Feb; 14(1):4354. PubMed ID: 38388539
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
[TBL] [Abstract][Full Text] [Related]
19. Identification of disulfidptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer.
Liang J; Wang X; Yang J; Sun P; Sun J; Cheng S; Liu J; Ren Z; Ren M
Front Immunol; 2023; 14():1198826. PubMed ID: 38035071
[TBL] [Abstract][Full Text] [Related]
20. A novel disulfidptosis-related lncRNAs signature for predicting survival and immune response in hepatocellular carcinoma.
Guo Z; Xie Y; Zhang L; Liu S; Jiang W
Aging (Albany NY); 2024 Jan; 16(1):267-284. PubMed ID: 38180745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
